in partnership with
DRC Logo

Treating AMD

March 13, 2019

There is no cure, or treatment, for dry age-related macular degeneration (AMD) at this time. Individuals diagnosed with advanced wet AMD can receive injections of therapeutic drugs in the eye to slow the progression of vision loss. Patients that are able to receive therapeutic injections will seek treatment with their eye doctor.

Approximately ninety-five percent of AMD patients are diagnosed with dry AMD. Researchers at the Retina Foundation are working diligently to find treatments for these individuals. Funding for this research is a crucial part of discovering treatments. Our AMD research is supported by individuals, foundations, and pharmaceutical/biotechnology corporations.

If you have any questions about clinical trials being conducted at the Retina Foundation, or would like more information, please contact our AMD clinical research staff at amdtrials@rfsw.org.

AMD CLINICAL STUDIES WE ARE CURRENTLY ENROLLING FOR:

Alexion
For detailed information go to clinicaltrials.gov NCT#: 05019521
Study Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Genentech GR42558
For detailed information go to clinicaltrials.gov NCT#: 03972709
Study Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)

Genentech GR42163
For detailed information go to clinicaltrials.gov  NCT#: 04615325
Study Title: A Phase Ia Multicenter, Open -Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogencity of Intravitreal Injections of RO7303359 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Gyroscope Horizon
For detailed information go to clinicaltrials.gov NCT#: 04566445
Study Title: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Ophthotech OPH2005
For detailed information go to clinicaltrials.gov NCT#: 03364153
Study Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

Ionis Golden
For detailed information go to clinicaltrials.gov NCT#: 03815825
Study Title: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

 

 

Treating AMD

Related Articles

Discovering New Therapies for AMD Measuring the Release of A Therapeutic Drug in a Controlled Lab Setting Reading Research Helped Madelyn iPad Game Study: Frequently Asked Questions Retina Foundation 20/20 Video Research Updates
Mailicon
Get the Latest Updates

Sign up to receive emails from Retina Foundation that will keep you up-to-date on our research and events.

  • This field is for validation purposes and should be left unchanged.
Contact Us

Contact Us

  • This field is for validation purposes and should be left unchanged.
x

Please check all that apply:

How did you learn about the
Retina Foundation?

  • Please check all that apply:
  • This field is for validation purposes and should be left unchanged.
Contact Us

Request an Appointment

Please complete this form if you are interested in speaking to a member of our team about your AMD.

all fields required

DOWNLOAD Printable Form